by valeo-adm | Mar 9, 2023 | News Release
MONTREAL, QUEBEC , March 9, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2023...
by valeo-adm | Feb 7, 2023 | Communiqué de presse
La couverture de remboursement public au Québec facilitera et élargira l’accès aux médicaments pour les patients atteints de la maladie de Parkinson au Québec MONTRÉAL (QUÉBEC), le 7 février 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2)...
by valeo-adm | Feb 7, 2023 | News Release
Quebec public reimbursement coverage to facilitate and expand medication access for Parkinson’s patients in Quebec MONTREAL, QUEBEC , February 7, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company,...
by valeo-adm | Jan 30, 2023 | Communiqué de presse, Uncategorized
Revenus trimestriels records de 12,7 millions $ en T4 2022, en hausse de 274 % comparativement au quatrième trimestre de 2021 Revenus records de 27,7 millions $ en 2022, en hausse de 105 % comparativement à 2021 Revenus records prévus pour le premier trimestre de 2023...
by valeo-adm | Jan 30, 2023 | News Release
Record quarterly revenues of $12.7 million in Q4-22, up 274% over Q4-21 Record revenues in 2022 of $27.7 million, up 105% over 2021 Record revenues forecasted in Q1-23 Creation of Ophthalmology Business Unit following the addition of XIIDRA® and SIMBRINZA®, expansion...
